Want to see ASTH full AI Analyst Report?
ASTH Stock Chart & Stats
$38.41
-$2.12(-5.26%)
At close: 4:00 PM EDT
$38.41
-$2.12(-5.26%)
Day’s Range― - ―
52-Week Range$18.08 - $51.60
Previous Close$38.19
Volume598.74K
Average Volume (3M)385.25K
Market Cap
$1.83B
Enterprise Value$2.66B
Total Cash (Recent Filing)$400.79M
Total Debt (Recent Filing)$979.41M
Price to Earnings (P/E)46.6
Beta1.09
Next Earnings
Nov 05, 2026EPS Estimate
0.46Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.83
Shares Outstanding49,604,366
10 Day Avg. Volume345,894
30 Day Avg. Volume385,248
Financial Highlights & Ratios
PEG Ratio-1.09
Price to Book (P/B)1.56
Price to Sales (P/S)0.38
P/FCF Ratio11.65
Enterprise Value/Market Cap1.45
Enterprise Value/Revenue0.69
Enterprise Value/Gross Profit7.49
Enterprise Value/Ebitda13.94
Forecast
1Y Price Target
$52.40Price Target Upside36.42% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
EPS Forecast (FY)1.4
Revenue Forecast (FY)$3.98B
Bulls Say, Bears Say
Bulls Say
Rapid Growth And Cash GenerationAstrana is scaling rapidly while converting growth into substantial operating and free cash flow. This combination supports continued investment in provider networks, care-management capabilities, and contract expansion, giving the company greater flexibility to compound its value-based care platform over the next several quarters.
Expanding Full-risk PlatformThe large membership base and high full-risk mix deepen Astrana’s exposure to value-based economics, where effective care coordination can improve medical-cost performance. Greater scale can strengthen payer and provider relationships while making its operating infrastructure more valuable across contracts.
AI-enabled Operating LeverageAutomation is producing measurable efficiency gains rather than serving only as a strategic narrative. Lower handling time, higher automated interaction capacity, and improved G&A leverage can support scalable growth, help manage administrative complexity, and strengthen margins if adoption continues.
Bears Say
Severe Margin CompressionThe sharp decline in gross and net margins shows that revenue expansion has not translated proportionately into durable profitability. Thin current margins leave less room to absorb medical-cost pressure or execution setbacks and make sustained earnings improvement dependent on operating leverage and better contract economics.
Debt Remains A Material BurdenRecent debt repayment is constructive, but the remaining debt load is still large relative to internally generated cash. Thin operating-cash-flow coverage can constrain capital allocation and leave the company more exposed if profitability, membership growth, or risk-contract performance weakens.
Medicaid Attrition And Cost PressureMedicaid membership attrition can reduce the scale and contribution of existing arrangements, while elevated commercial cost trends pressure risk-contract economics. Together, these factors may complicate forecasting and require continued portfolio rebalancing and tighter medical-cost management.
ASTH FAQ
What was Astrana Health’s price range in the past 12 months?
Astrana Health lowest stock price was $18.08 and its highest was $51.60 in the past 12 months.
What is Astrana Health’s market cap?
Astrana Health’s market cap is $1.83B.
When is Astrana Health’s upcoming earnings report date?
Astrana Health’s upcoming earnings report date is Nov 05, 2026 which is in 15 days.
How were Astrana Health’s earnings last quarter?
Astrana Health released its earnings results on Aug 06, 2026. The company reported $0.4 earnings per share for the quarter, beating the consensus estimate of $0.336 by $0.064.
Is Astrana Health overvalued?
According to Wall Street analysts Astrana Health’s price is currently Undervalued.
Does Astrana Health pay dividends?
Astrana Health does not currently pay dividends.
What is Astrana Health’s EPS estimate?
Astrana Health’s EPS estimate is 0.46.
How many shares outstanding does Astrana Health have?
Astrana Health has 49,604,366 shares outstanding.
What happened to Astrana Health’s price movement after its last earnings report?
Astrana Health reported an EPS of $0.4 in its last earnings report, beating expectations of $0.336. Following the earnings report the stock price went up 4.776%.
Which hedge fund is a major shareholder of Astrana Health?
Currently, no hedge funds are holding shares in ASTH
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Astrana Health Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$52.40 (36.42% Upside)
$52.40 (36.42% Upside)
Blogger Sentiment
Bullish
ASTH Sentiment 75%
Sector Average 67%
Sector Average 67%
Hedge Fund Trend
Decreased
By 245.7K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▼ 4.5%
Last 30 Days ▲ 16.4%
Last 30 Days ▲ 16.4%
Technicals
SMA
Positive
20 days / 200 days
Momentum
16.94%
12-Months-Change
Fundamentals
Return on Equity
5.09%
Trailing 12-Months
Asset Growth
58.22%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Astrana Health
Astrana Health, Inc., which rebranded from Apollo Medical Holdings, Inc. in February 2024, is a healthcare management firm based in Alhambra, California, founded in 1985. This company delivers medical services throughout the United States, operating with a physician-centered approach powered by advanced technology. Its operations are structured across three distinct divisions: Care Partners, Care Delivery, and Care Enablement. Astrana Health utilizes its exclusive platform for population health management and healthcare delivery to implement an integrated, value-based care model. This strategic approach empowers the healthcare providers within its network to offer high-quality care to their patients. The organization provides extensive care coordination services to a broad spectrum of stakeholders, including patients, their families, primary care physicians, specialists, acute care hospitals, other inpatient facilities, physician groups, and health plans. Its robust physician network encompasses primary care doctors, specialized practitioners, advanced practice providers (extenders), and hospital-based physicians. Astrana Health serves a diverse patient base, primarily those with insurance coverage—such as private plans, Medicare, Medicaid, and HMOs—but also extends care to uninsured individuals.
ASTH Company Deck
ASTH Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed strong operational and financial momentum: substantial year-over-year top-line and profitability growth, improved operating leverage from AI-driven automation, meaningful cash generation and accelerated de-leveraging, successful integration of Prospect with expected synergies, and raised EBITDA guidance. Offsetting these positives are ongoing Medicaid membership attrition and program-specific headwinds in California, slightly elevated commercial cost trends, a minor one-time $15 million ACO REACH revenue reduction, and some uncertainty around exchange and Medicaid dynamics. On balance, the positive execution, scale gains, and trajectory of the AI-native operating system materially outweigh the near-term challenges and conservatively guided risks.View all ASTH earnings summariesASTH Stock 12 Month Forecast
All Analysts
Top Analysts
Average Price Target
$52.40
▲(36.42% Upside)
Technical Analysis
1 Day
3 Days
1 Week
1 Month
Clinigence Holdings
―
InnovAge Holding
―
Agilon Health
―
Aveanna Healthcare Holdings
―
P3 Health Partners
―
Ownership Overview
36.11% Insiders
16.57% Mutual Funds
1.36% Other Institutional Investors
19.85% Public Companies and
Individual Investors









